Beta blockers in @entity453 with and without XXXX .

@entity7971 @entity712 @entity101 @entity731 @entity26 @entity951 @entity453 @entity583 @entity943
Beta-adrenergic blockers (BB) were developed to treat @entity951 . Trials of BB with @entity583 ( @entity583 ) setting were highly successful in the pre-thrombolytic @entity7971 . Subsequently BB proved to be beneficial in post-thrombolytic @entity583 in long-term use. In stable @entity951 BB gives good symptomatic relief primarily by reducing myocardial @entity26 demand. In the set-up of unstable @entity951 /non-ST elevation @entity583 they prevent @entity943 and progression to ST elevation @entity583 . BB have also been shown to retard the progression of @entity731 . In @entity712 ( @entity712 ) they are now the first-line drugs with ACE inhibitors to impart prognostic benefit. Their role in improving outcome of cardiac and non-cardiac surgeries has found good evidence and recommendation. But in the field where BB have scored maximally, ie, in @entity101 , their role is recently debated. But the unchallenged fact remains that in presence of any form of @entity453 , BB are the most preferred class of drugs to treat @entity101 .
